(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(pyridin-4-yl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(pyridin-4-yl)methanone
• 英文别名: [3-(4-Methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone；[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]-pyridin-4-ylmethanone
• 化学式: C₂₂H₁₉N₃O₂
• 分子量: 357.412
• InChiKey: DVJDNDRDULERKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  苯乙酮 在 溶剂黄146 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 (5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazol-1-yl)(pyridin-4-yl)methanone
  参考文献：
  名称：

  吡唑啉衍生物的设计，合成，拓扑异构酶I和II的抑制活性，抗增殖活性和构效关系研究：一种具有ATP竞争性的人类拓扑异构酶IIα催化抑制剂

  摘要：

  从查耳酮（3）和酰肼（4）合成了一系列吡唑啉衍生物（5），产率为92–96％。随后，对topo-I和IIα介导的舒张和抗增殖活性测定进行了评估5。在测试的化合物中，浓度为100μM的5h的topo-I活性非常强，为97％（喜树碱，74％）。尽管如此，所有化合物5a – 5i在相同浓度下显示出显着的topo II抑制活性，范围为90-94％（依托泊苷，96％）。在一组三种人类肿瘤细胞系HCT15，BT474和T47D中测试了这些化合物的细胞毒性潜力。所有化合物均在1.9-10.4μM的范围内显示出对HCT15细胞系的强活性，IC 50为（阿霉素23.0；依托泊苷6.9；喜树碱7.1μM）。此外，观察到化合物5c，5f和5i对BT474细胞系具有强的抗增殖活性。由于化合物5d在非常低的IC 50下显示出抗增殖活性，因此5d然后选择了ATP，通过多种ATP竞争测定，ATPase测定和DNA-to

  DOI：

  10.1016/j.bmc.2016.03.017

文献信息

• 10.14233/ajchem.2024.31666
  作者：Birudala, Geetha、Singh, Gurinderdeep、Nayeem, S. Abdur Rahman Junaid、Padmavathi、Pingali, Srinivasa Rao、Vaishali、Dighe, Rajendra Dnyandeo

  DOI：10.14233/ajchem.2024.31666

  日期：——

  This study explores the synthesis, in silico behaviour and antimicrobial activity of isoniazid derived 2-pyrazolines as potential drugs for tuberculosis and bacterial infections. The investigation encompasses the synthesis, computational studies for molecular behaviour and antimicrobial efficacy assessment. Incorporating established drugs like isoniazid is explored to enhance their pharmacological properties. The synthesized compounds were characterized by analytical techniques such as IR, NMR, mass spectral analysis and elemental analysis. Synthesized pyrazolines 4a-j were evaluated for in vitro antitubercular and antibacterial activities against various biological strains. In silico analysis provides valuable insights into ADMET descriptors, confirming good pharmacokinetic properties. This suggests these compounds as templates for developing new anti-mycobacterial agents, guiding the design of novel compounds with improved therapeutic potential.
• Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure–activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor
  作者：Pervez Ahmad、Hyunjung Woo、Kyu-Yeon Jun、Adnan A. Kadi、Hatem A. Abdel-Aziz、Youngjoo Kwon、A.F.M. Motiur Rahman

  DOI：10.1016/j.bmc.2016.03.017

  日期：2016.4

  A series of pyrazoline derivatives (5) were synthesized in 92–96% yields from chalcones (3) and hydrazides (4). Subsequently, topo-I and IIα-mediated relaxation and antiproliferative activity assays were evaluated for 5. Among the tested compounds, 5h had a very strong topo-I activity of 97% (Camptothecin, 74%) at concentration of 100 μM. Nevertheless, all the compounds 5a–5i showed significant topo

  从查耳酮（3）和酰肼（4）合成了一系列吡唑啉衍生物（5），产率为92–96％。随后，对topo-I和IIα介导的舒张和抗增殖活性测定进行了评估5。在测试的化合物中，浓度为100μM的5h的topo-I活性非常强，为97％（喜树碱，74％）。尽管如此，所有化合物5a – 5i在相同浓度下显示出显着的topo II抑制活性，范围为90-94％（依托泊苷，96％）。在一组三种人类肿瘤细胞系HCT15，BT474和T47D中测试了这些化合物的细胞毒性潜力。所有化合物均在1.9-10.4μM的范围内显示出对HCT15细胞系的强活性，IC 50为（阿霉素23.0；依托泊苷6.9；喜树碱7.1μM）。此外，观察到化合物5c，5f和5i对BT474细胞系具有强的抗增殖活性。由于化合物5d在非常低的IC 50下显示出抗增殖活性，因此5d然后选择了ATP，通过多种ATP竞争测定，ATPase测定和DNA-to